Optimi Health SEC Filings

Optimi Health Corp. filed a Form 6-K highlighting the completion of its first export of naturally derived psilocybin to the United Kingdom to support a planned Phase 2 clinical trial. The shipment includes psilocybin biomass and finished 5mg capsules made at its GMP facility in Princeton, British Columbia.

The capsules use the same formulation already prescribed to patients in Australia for treatment-resistant depression, showing that Optimi is leveraging an existing commercial product for research use. Manufacturing and export were conducted under Health Canada’s Drug Establishment Licence framework and required export authorization from Health Canada and import authorization from the UK Home Office.

By supplying both biomass and finished drug product from a single licensed, GMP-compliant site, Optimi presents itself as a vertically integrated supplier of psilocybin and MDMA products for regulated mental health therapies and clinical research markets internationally.

Optimi Health Corp. reported progress on its ibogaine initiative, securing naturally derived ibogaine from two sources in both hydrochloride and freebase forms. The company plans to begin finished drug product development this summer at its GMP facility in British Columbia, initially targeting encapsulated 50mg and 100mg doses.

The update follows an April 2026 U.S. executive order that prioritized ibogaine and other psychedelic therapies for accelerated FDA review and expanded patient access, increasing demand for reliable GMP-grade supply. In Canada, ibogaine is regulated as a prescription drug rather than a controlled substance, which, combined with Optimi’s existing Health Canada licenses, positions the company to manufacture and supply ibogaine for research and regulated access.

Optimi already produces validated MDMA and botanical psilocybin products and supplies active ingredients and finished dosages to international clinical and therapeutic programs, including Australia’s Authorized Prescriber Scheme and Canada’s Special Access Program.

Optimi Health Corp. reported progress on its ibogaine initiative, securing naturally derived ibogaine from two sources in both hydrochloride and freebase forms. The company plans to begin finished drug product development this summer at its GMP facility in British Columbia, initially targeting encapsulated 50mg and 100mg doses.

The update follows an April 2026 U.S. executive order that prioritized ibogaine and other psychedelic therapies for accelerated FDA review and expanded patient access, increasing demand for reliable GMP-grade supply. In Canada, ibogaine is regulated as a prescription drug rather than a controlled substance, which, combined with Optimi’s existing Health Canada licenses, positions the company to manufacture and supply ibogaine for research and regulated access.

Optimi already produces validated MDMA and botanical psilocybin products and supplies active ingredients and finished dosages to international clinical and therapeutic programs, including Australia’s Authorized Prescriber Scheme and Canada’s Special Access Program.

Optimi Health Corp. completed a GMP production run of its 5mg psilocybin capsules, the same formulation already prescribed in Australia for treatment-resistant depression. Some of this batch will support upcoming clinical research in the United States and clinical trials in Europe across multiple indications.

The company carried out all stages of manufacturing in-house at its Health Canada Drug Establishment Licence facility in British Columbia, from biomass cultivation and API extraction to encapsulation and packaging. Optimi is authorized to hold substantial quantities of psilocybin and biomass on site, positioning it as a vertically integrated supplier of regulated psychedelic drug products.

Optimi already supplies psilocybin and MDMA products to regulated markets, including patient prescriptions in Australia under the Authorized Prescriber Scheme and access in Canada through the Special Access Program, supporting both current patient use and ongoing clinical research.

Optimi Health Corp. completed a GMP production run of its 5mg psilocybin capsules, the same formulation already prescribed in Australia for treatment-resistant depression. Some of this batch will support upcoming clinical research in the United States and clinical trials in Europe across multiple indications.

The company carried out all stages of manufacturing in-house at its Health Canada Drug Establishment Licence facility in British Columbia, from biomass cultivation and API extraction to encapsulation and packaging. Optimi is authorized to hold substantial quantities of psilocybin and biomass on site, positioning it as a vertically integrated supplier of regulated psychedelic drug products.

Optimi already supplies psilocybin and MDMA products to regulated markets, including patient prescriptions in Australia under the Authorized Prescriber Scheme and access in Canada through the Special Access Program, supporting both current patient use and ongoing clinical research.

Optimi Health Corp. reports on updated rules in Australia that expand access to psychedelic-assisted therapy using prescribed MDMA and psilocybin. The Therapeutic Goods Administration’s revised Authorized Prescriber framework broadens therapist eligibility, allows treatment in more medically supervised settings, and is intended to support scaling of commercial programs.

Aggregated data show no serious adverse events reported under the scheme since December 2025, reinforcing the real-world safety profile. Reimbursement now spans public programs such as DVA, NDIS and WorkCover, as well as private insurance via Medibank. Optimi, which manufactures GMP-grade MDMA and psilocybin in Canada, highlights its ability to supply these regulated therapies to Australian patients.

Optimi Health Corp. reports on updated rules in Australia that expand access to psychedelic-assisted therapy using prescribed MDMA and psilocybin. The Therapeutic Goods Administration’s revised Authorized Prescriber framework broadens therapist eligibility, allows treatment in more medically supervised settings, and is intended to support scaling of commercial programs.

Aggregated data show no serious adverse events reported under the scheme since December 2025, reinforcing the real-world safety profile. Reimbursement now spans public programs such as DVA, NDIS and WorkCover, as well as private insurance via Medibank. Optimi, which manufactures GMP-grade MDMA and psilocybin in Canada, highlights its ability to supply these regulated therapies to Australian patients.

Optimi Health Corp. Schedule 13G reports that YA II PN, Ltd. and affiliated entities collectively beneficially own 400,000 shares of common stock, equal to 7.1% of the class. The filing lists shared voting and dispositive power over 400,000 shares and identifies related entities and Mark Angelo as the decisionmaker.

The filing names YA Global Investments II (U.S.), Yorkville Advisors Global, Yorkville Advisors Global II, LLC, YAII GP, YAII GP II, LLC, SC-Sigma Global Partners and Mark Angelo as affiliates that may be deemed to beneficially own the same 400,000 shares. Signatures show the filing activity dated in May 2026.

Optimi Health Corp. Schedule 13G reports that YA II PN, Ltd. and affiliated entities collectively beneficially own 400,000 shares of common stock, equal to 7.1% of the class. The filing lists shared voting and dispositive power over 400,000 shares and identifies related entities and Mark Angelo as the decisionmaker.

The filing names YA Global Investments II (U.S.), Yorkville Advisors Global, Yorkville Advisors Global II, LLC, YAII GP, YAII GP II, LLC, SC-Sigma Global Partners and Mark Angelo as affiliates that may be deemed to beneficially own the same 400,000 shares. Signatures show the filing activity dated in May 2026.

Optimi Health Corp. reported a manufacturing milestone with completion of a production run of naturally derived psilocybin extract containing approximately 6% psilocybin, the highest-purity botanical extract the company has produced so far. This reflects gains in its mushroom cultivation program and extraction process.

A portion of this higher-purity extract is earmarked for upcoming sponsor-led clinical research programs in Europe, while the remainder supports ongoing product development and future regulated supply. The milestone also strengthens Optimi’s commercial supply of naturally derived 5 mg psilocybin capsules for treatment-resistant depression under Australia’s Authorised Prescriber Scheme, where aggregated data show no serious adverse events as of December 2025.

Optimi Health Corp. is registering 2,400,000 common shares in an initial public offering in the United States.

The prospectus also registers warrants to purchase up to 110,400 common shares (Underwriter Warrants) and up to 110,400 common shares issuable upon exercise of those Underwriter Warrants at a price equal to 120% of the IPO price. The IPO price is US$6.25 per share, with gross proceeds of US$15,000,000 before underwriting discounts. Proceeds to the issuer before expenses are shown as US$13,875,000. The underwriter has a 45-day option to purchase up to an additional 360,000 shares for over-allotments. Shares outstanding giving effect to the offering (assuming no over-allotment) are based on 3,225,899 common shares issued and outstanding as of the date of the prospectus.

Optimi Health Corp. is filing a preliminary prospectus for an initial public offering of 2,500,000 common shares and registration of up to 115,000 Underwriter Warrants (and 115,000 shares issuable on exercise). The prospectus states an expected price range of US$6.00 to US$8.00 per share and an underwriter overallotment option of 375,000 shares.

The company is a Canadian GMP-compliant manufacturer of MDMA and botanical psilocybin products with Health Canada licences (DEL, Dealer’s Licence, Precursor Licence), supplies prescription markets in Australia and access via Canada’s Special Access Program, and reports fiscal 2025 net loss of C$3,712,031 with an accumulated deficit of C$27,241,680 as of December 31, 2025. The board has approved a 1-for-30 Reverse Share Split intended to satisfy Nasdaq price requirements; Nasdaq listing is a condition to completing the offering.